RETRACTION: Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma (Retraction of Vol 34, Pg E104, 2016)

被引：0
|
作者：
Smyth
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 27期
关键词：
D O I：
10.1200/JCO.23.01358
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4448 / 4448
页数：1
相关论文
共 50 条
  • [21] Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma
    Wu, Xinqi
    Giobbie-Hurder, Anita
    Connolly, Erin M.
    Li, Jingjing
    Liao, Xiaoyun
    Severgnini, Mariano
    Zhou, Jun
    Rodig, Scott
    Hodi, F. Stephen
    ONCOIMMUNOLOGY, 2018, 7 (07):
  • [22] RETRACTION: Anti-carcinogenic activity of anandamide on human glioma in vitro and in vivo (Retraction of Vol 13, Pg 1558, 2016)
    Ma, Chao
    Wu, Ting-Ting
    Jiang, Pu-Cha
    Li, Zhi-Qiang
    Chen, Xin-Jun
    Fu, Kai
    Wang, Wei
    Gong, Rui
    MOLECULAR MEDICINE REPORTS, 2023, 27 (04)
  • [23] Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
    Afzal, Muhammad Zubair
    Mabaera, Rodwell
    Shirai, Keisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [24] IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinoma
    Cui, Chuanliang
    Li, Juan
    Yang, Yue
    Si, Lu
    Chi, Zhihong
    Mao, Lili
    Wang, Xuan
    Tang, Bixia
    Yan, Xieqiao
    Li, Siming
    Zhou, Li
    Wei, Xiaoting
    Shen, Yuping
    Guo, Qun
    Zheng, Shirui
    Guo, Jun
    Lian, Bin
    INNOVATION, 2024, 5 (04):
  • [25] Combination of lactate dehydrogenase and tumor mutational burden to predict clinical benefit of anti-CTLA-4 therapy in melanoma
    Xiao, Wenjing
    Du, Nan
    Huang, Taoyuan
    Guo, Jinan
    Mo, Xing-kui
    Yuan, Tao
    Chen, Yong
    Ye, Ting
    Xu, Chunwei
    Wang, Wen xian
    Wang, Guoqiang
    Cai, Shangli
    Chen, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Combination of PV-10 immunochemoablation and systemic anti-CTLA-4 antibody therapy in murine models of melanoma
    Wachter, Eric A.
    Blair, Savannah
    Singer, Jamie
    Dees, Craig
    CANCER RESEARCH, 2013, 73 (08)
  • [27] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    Bowyer, S.
    Prithviraj, P.
    Lorigan, P.
    Larkin, J.
    McArthur, G.
    Atkinson, V.
    Millward, M.
    Khou, M.
    Diem, S.
    Ramanujam, S.
    Kong, B.
    Liniker, E.
    Guminski, A.
    Parente, P.
    Andrews, M. C.
    Parakh, S.
    Cebon, J.
    Long, G. V.
    Carlino, M. S.
    Klein, O.
    BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1084 - 1089
  • [28] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    S Bowyer
    P Prithviraj
    P Lorigan
    J Larkin
    G McArthur
    V Atkinson
    M Millward
    M Khou
    S Diem
    S Ramanujam
    B Kong
    E Liniker
    A Guminski
    P Parente
    M C Andrews
    S Parakh
    J Cebon
    G V Long
    M S Carlino
    O Klein
    British Journal of Cancer, 2016, 114 : 1084 - 1089
  • [29] ANTI-CTLA-4 ANTIBODY THERAPY (IPILIMUMAB) INDUCED LUPUS-LIKE SKIN MANIFESTATIONS IN A METASTATIC MELANOMA PATIENT
    Calder, K.
    Armstrong, C.
    Hiatt, K.
    Smoller, B.
    Cheung, W.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2011, 38 (01) : 93 - 93
  • [30] Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma
    Bajor, David L.
    Mick, Rosemarie
    Riese, Matthew J.
    Richman, Lee P.
    Xu, Xiaowei
    Torigian, Drew A.
    Stelekati, Erietta
    Sweeney, Martha
    Sullivan, Brendan
    Schuchter, Lynn M.
    Amaravadi, Ravi
    Wherry, E. John
    Vonderheide, Robert H.
    CANCER RESEARCH, 2015, 75
12345